Heterogeneous Treatment Effects of High-Frequency Oscillatory Ventilation for Acute Respiratory Distress Syndrome: A Post Hoc Analysis of the Oscillation for Acute Respiratory Distress Syndrome Treated Early (OSCILLATE) Trial

OBJECTIVES: We sought to evaluate whether different subgroups of adults with acute respiratory distress syndrome (ARDS) respond differently to high-frequency oscillatory ventilation (HFOV). DESIGN: The Oscillation for ARDS Treated Early (OSCILLATE) trial was a randomized controlled trial of HFOV vs....

Full description

Saved in:
Bibliographic Details
Published inCritical care explorations Vol. 6; no. 11; p. e1178
Main Authors Kobayashi, Hirotada, Angriman, Federico, Ferguson, Niall D., Adhikari, Neill K. J.
Format Journal Article
LanguageEnglish
Published Hagerstown, MD Lippincott Williams & Wilkins 01.11.2024
Wolters Kluwer
Subjects
Online AccessGet full text
ISSN2639-8028
2639-8028
DOI10.1097/CCE.0000000000001178

Cover

More Information
Summary:OBJECTIVES: We sought to evaluate whether different subgroups of adults with acute respiratory distress syndrome (ARDS) respond differently to high-frequency oscillatory ventilation (HFOV). DESIGN: The Oscillation for ARDS Treated Early (OSCILLATE) trial was a randomized controlled trial of HFOV vs. conventional ventilation that found an increased risk of in-hospital mortality (primary outcome) with HFOV. In a post hoc analysis, we applied three different approaches to evaluate heterogeneity of treatment effect for in-hospital mortality: 1) subgroup analyses based on baseline Pao2:Fio2 ratio and oxygenation index (OI); 2) a risk-based approach using a multivariable outcome prediction model; and 3) a clustering approach via multivariable latent class analysis. We used multivariable logistic regression models to assess for interaction. SETTING: Thirty-nine ICUs, five countries. SUBJECTS: Five hundred forty-eight adults with moderate to severe ARDS. INTERVENTIONS: HFOV vs. conventional mechanical ventilation with low tidal volume and higher positive end-expiratory pressure. MEASUREMENTS AND MAIN RESULTS: The effect of HFOV on in-hospital mortality was consistent across categories of Pao2:Fio2 ratio (adjusted odds ratio [aOR], 2.04; 95% CI, 1.32-3.17 and aOR, 1.16; 95% CI, 0.49-2.75 for groups with Pao2:Fio2 above or equal to 80, vs. below 80, respectively; interaction p = 0.23) and OI (aOR, 1.78; 95% CI, 0.67-4.70; aOR, 3.19; 95% CI, 1.44-7.09; aOR, 1.73; 95% CI, 0.82-3.65; and aOR, 1.33; 95% CI, 0.61-2.90 for quartiles of baseline OI, respectively; interaction p = 0.44). Point estimates for the effect of HFOV were consistent across risk categories (aOR, 2.44; 95% CI, 0.40-14.83; aOR, 1.69; 95% CI, 0.75-3.85; and aOR, 2.10; 95% CI, 0.59-7.54 for the lowest, moderate, and highest risk categories, respectively; interaction p = 0.32). Using a clustering approach, point estimates for HFOV were also consistent (cluster 1: aOR, 1.85; 95% CI, 1.15-3.00 and cluster 2: aOR, 1.75; 95% CI, 0.91-3.38; interaction p = 0.75). CONCLUSIONS: We did not identify heterogeneity in the effect of HFOV across different subgroups of patients with ARDS.
Bibliography:Drs. Angriman and Adhikari contributed equally to this work. The authors have disclosed that they do not have any potential conflicts of interest. Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (http://journals.lww.com/ccejournal). For information regarding this article, E-mail: neill.adhikari@utoronto.ca
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:2639-8028
2639-8028
DOI:10.1097/CCE.0000000000001178